Does Tirzepatide Cause Hair Loss? Why It Happens and What Helps

Key takeaways

• Yes, in some people. On the Zepbound label, hair loss was reported by 5, 4 and 5% of people on 5, 10 and 15 mg versus 1% on placebo, by 7.1% of women versus 0.5% of men, and the label associates it with weight reduction. Semaglutide 2.4 mg: 3.3% versus 1%.
• The likely mechanism is telogen effluvium: rapid weight loss or a sharp drop in food intake pushes many follicles into their resting phase at once, and the hairs fall two to three months later, as they often do after bariatric surgery.
• It is usually temporary. Acute telogen effluvium resolves in about 95% of cases, and hair tends to regain its fullness within six to nine months once the trigger passes.
• What helps: enough food and protein, a blood test, and treating only the deficiencies actually found, such as low iron; a slower escalation if weight is falling very fast. Minoxidil's evidence is for pattern hair loss, not this kind of shedding.
• What does not: biotin without a deficiency (it can also distort blood tests), high-dose vitamin A or selenium, and peptide hair products. See a dermatologist for shedding beyond six months, patches, scalp symptoms or a widening part.

The short answer

Tirzepatide can cause hair loss, but mostly indirectly: the shedding follows the weight loss, not the drug itself. In the Zepbound trials 4 to 5% of people reported hair loss against 1% on placebo, nearly all of them women, and none stopped treatment because of it. The pattern fits telogen effluvium, a temporary shedding that starts two to three months after rapid weight loss and grows back over months. Eating enough protein and correcting real deficiencies help; biotin and hair peptides do not. This page belongs to our GLP-1 side effects guide, and its sibling covers how to get rid of sulfur burps.

What the labels show

Sources: Zepbound label, pooled 72-week trials (2,519 people on the drug); Wegovy label, pooled 68-week trials at 2.4 mg and 72-week trials at 7.2 mg (Zepbound label) (Wegovy label).

Three things stand out. Women carry almost all of it: about one woman in 14 on tirzepatide reported hair loss, against one man in 200. Tirzepatide's rate did not climb with the dose (5, 4, 5%), even though weight loss did. And the cleanest dose comparison is semaglutide's own: in the same trials, 7.2 mg produced more hair loss than 2.4 mg (5.8% versus 3.3%), consistent with larger weight loss bringing more shedding. Whether tirzepatide or semaglutide causes more hair loss cannot be read from the labels, because their trials differed and no head-to-head trial has reported it. Neither label says what kind of hair loss was seen; the trials recorded reports, not dermatologist diagnoses.

Why it happens: telogen effluvium

Each scalp follicle cycles through a growing phase (anagen, two to five years, about 90% of hairs at any time), a short transition (catagen, a few weeks) and a resting phase (telogen, about three to five months, about 10% of hairs), after which the resting hair is shed. A physical stress can push many growing follicles into the resting phase at once, and two to three months later they shed together. Triggers include surgery, high fever, illness, childbirth, severe protein, fatty acid or zinc deficiency, and caloric restriction (Asghar 2020). The American Academy of Dermatology lists losing 20 pounds or more among the causes of excessive shedding (AAD).

Bariatric surgery is the closest model. A meta-analysis of 18 studies (2,538 patients) found hair loss in 57% of people after weight-loss surgery; it became less common with longer follow-up, and it was more frequent in younger patients, possibly more so in women, and in people with lower zinc, folic acid and ferritin levels (Zhang 2021). The rates on the drug labels are far lower, and the studies measured hair loss differently, so the comparison is loose; the shared feature is fast weight loss on much less food.

On a GLP-1, intake falls sharply: the 2025 joint advisory of four US obesity and nutrition societies cites reductions of 16 to 39% in calories, warns that below about 1,200 kcal a day for women or 1,800 for men vitamin and mineral needs become hard to meet, and lists excessive hair loss among the signs of frank nutrient deficiency (Mozaffarian 2025). Whether tirzepatide also acts directly on the hair follicle has not been shown in people.

When it starts and when it grows back

Sources: (Asghar 2020) (AAD). The six-to-nine-month recovery comes from the AAD's description of shedding after childbirth, the best-documented trigger. Normal shedding is 50 to 100 hairs a day, and the AAD notes that if the stressor stays, shedding can persist. On a GLP-1 that means shedding can continue for as long as weight is falling fast or intake stays very low.

What helps

Eat enough, with enough protein. Severe protein deficiency and caloric restriction are recognized triggers (Asghar 2020). The joint advisory notes that protein targets of 1.2 to 1.6 g per kg a day have been proposed during active weight loss, suggests an absolute 80 to 120 g a day may be easier to follow, and warns against going below 0.4 to 0.5 g per kg (Mozaffarian 2025). No study has tested protein for GLP-1 hair loss, but it addresses a known trigger and protects muscle as well.

Test, then correct what is actually low. A 2019 review of vitamins, minerals and hair loss found that most authors agree on iron supplementation when iron or ferritin is low and hair is shedding, although trials of iron replacement in telogen effluvium are few; that zinc deficiency causes hair loss that regrows with zinc, but that zinc levels in telogen effluvium are inconsistent and routine zinc screening is not recommended (Almohanna 2019). Thyroid disorders also disrupt the hair cycle and should be treated (Asghar 2020). The practical sequence is a clinician visit and blood tests, then targeted treatment, not a cabinet of supplements: the same review notes that too much vitamin A or selenium can itself cause hair loss.

Slow the weight loss if it is very fast. The trigger is the speed and depth of the loss, so a slower escalation or a lower maintenance dose, both allowed by the Zepbound label, may reduce shedding. That is plausible rather than proven; no trial has tested it for hair. If you use a compounded vial, confirm your dose with the units converter, because an accidental overdose speeds everything up.

Minoxidil, with honest expectations. Topical minoxidil has large trials for pattern hair loss, which our hair growth guide summarizes. For telogen effluvium the evidence is thin: a review describes minoxidil and finasteride as "neither efficient catagen inhibitors nor anagen inducers" (Asghar 2020), and the only study in chronic telogen effluvium is an uncontrolled retrospective series of 36 women on low-dose oral minoxidil (0.25 to 2.5 mg daily), whose shedding scores fell over 12 months; 13 developed facial hair growth, the authors called for placebo-controlled trials, and the paper discloses a patent application on the method (Perera 2017). We found no controlled trial of minoxidil in acute shedding of the kind that follows weight loss.

What does not help

Biotin, unless you are deficient. True biotin deficiency is rare in people eating a normal diet. The reported cases in which biotin improved hair all had an underlying cause of deficiency, and the 2019 review found no support for biotin in telogen effluvium or pattern hair loss. High-dose biotin also interferes with many laboratory tests, including thyroid tests and troponin; the review cites an FDA report of a falsely low troponin that led to a missed heart attack and a death (Almohanna 2019). If you take it, tell whoever orders your blood work.

Peptide hair products. Copper peptide serums have small, short studies at best, and injectable 'hair peptides' have no controlled human evidence and no legal source in the United States; our peptide hair growth guide grades each one.

Stopping the drug on your own. The hairs being shed entered their resting phase months earlier, so stopping does not bring them back, and in the Zepbound trials no one on the drug stopped because of hair loss (Zepbound label). Stopping usually means the weight returns. Discuss the dose instead.

When to see a dermatologist

• Shedding that lasts more than six months, which points to chronic telogen effluvium or another cause (Asghar 2020).
• Bald patches rather than diffuse thinning, or a red, scaly, itchy or painful scalp.
• A widening part or receding hairline that does not recover, which suggests pattern hair loss developing alongside.
• Loss of eyebrows, eyelashes or body hair.
• Shedding together with fatigue beyond what you expected, feeling cold, brittle nails or heavy periods, which call for blood tests.

The AAD's advice is not to wait if you are worried, because treatment that starts sooner tends to work better (AAD). For the rest of tirzepatide's safety profile, see is tirzepatide safe.

Frequently asked questions

+−Does Zepbound cause hair loss?

In some people, mostly indirectly. In the two placebo-controlled weight-loss trials on the Zepbound label, hair loss was reported by 5, 4 and 5 percent of people on 5, 10 and 15 mg, against 1 percent on placebo, and by 7.1 percent of women versus 0.5 percent of men. The label says the hair loss was associated with weight reduction, and no one on tirzepatide stopped the drug because of it.

+−Why does tirzepatide cause hair loss?

Most likely through the weight loss rather than a direct effect on hair. Rapid weight loss, a sharp drop in food intake or too little protein can push a large share of scalp follicles into their resting phase at once, a pattern called telogen effluvium; those hairs fall out two to three months later. The same shedding is common after bariatric surgery. Whether tirzepatide also acts on the follicle directly has not been shown.

+−Is tirzepatide hair loss reversible, and how long does it last?

Usually yes. Acute telogen effluvium lasts under six months and resolves in about 95 percent of cases, and in its best-documented example, shedding after childbirth, the American Academy of Dermatology says hair tends to regain its normal fullness within six to nine months. Shedding can continue while the trigger continues, for example during ongoing rapid weight loss or very low intake. Shedding beyond six months, patches or a thinning part line need a dermatologist.

+−Is hair loss worse on tirzepatide or semaglutide?

The labels cannot settle it. Hair loss was 4 to 5 percent on tirzepatide and 3.3 percent on semaglutide 2.4 mg, each against 1 percent on placebo, but those were different trials, and no head-to-head trial has reported hair loss. The cleanest dose comparison is within semaglutide's own trials: 5.8 percent at 7.2 mg versus 3.3 percent at 2.4 mg, consistent with more weight loss bringing more shedding. In both drugs, women were affected far more than men.

+−What is the best tirzepatide hair loss treatment?

Time, food and a blood test. Telogen effluvium usually regrows on its own over months. Eat enough, with adequate protein (a 2025 joint advisory notes targets of 1.2 to 1.6 g per kg a day have been proposed during weight loss), ask your clinician to check iron stores and treat any deficiency that is actually found, and discuss a slower escalation if weight is falling very fast. Minoxidil has trials for pattern hair loss, not for this kind of shedding.

+−Should I take biotin for hair loss on tirzepatide?

Not unless you are deficient, which is rare. Reviews find no evidence that biotin helps telogen effluvium or pattern hair loss in people with normal levels; the reported successes were in people with an underlying cause of deficiency. High-dose biotin can also distort common blood tests, including thyroid tests, which are often ordered when hair is shedding. Tell your clinician if you take it.

+−Should I stop tirzepatide if my hair is falling out?

Talk to your prescriber first. In the Zepbound trials no one on the drug stopped because of hair loss, and the shedding reflects a trigger that happened months earlier, so stopping does not bring those hairs back. A prescriber may slow the escalation, settle on a lower maintenance dose, or look for a deficiency or another cause. Stopping usually means the weight returns.

Sources

1. LabelEli Lilly. Zepbound (tirzepatide) injection, for subcutaneous use: prescribing information, revised August 2026 (DailyMed setid 487cd7e7-434c-4925-99fa-aa80b1cc776b). (2026)
2. LabelNovo Nordisk. Wegovy (semaglutide) injection and tablets: prescribing information, revised June 2026 (DailyMed setid ee06186f-2aa3-4990-a760-757579d8f77b). (2026)
3. ReviewAsghar F et al. Telogen effluvium: a review of the literature. Cureus 2020;12:e8320. (2020)
4. SourceAmerican Academy of Dermatology. Do you have hair loss or hair shedding? Public education page (accessed October 10, 2026).
5. ReviewZhang W et al. Hair loss after metabolic and bariatric surgery: a systematic review and meta-analysis. Obes Surg 2021;31:2649-59. (2021)
6. ReviewAlmohanna HM et al. The role of vitamins and minerals in hair loss: a review. Dermatol Ther (Heidelb) 2019;9:51-70. (2019)
7. StudyPerera E, Sinclair R. Treatment of chronic telogen effluvium with oral minoxidil: a retrospective study. F1000Res 2017;6:1650. (2017)
8. GuidelineMozaffarian D et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society. Am J Clin Nutr 2025;122:344-67. (2025)